U.S. Markets closed

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.64-0.03 (-0.53%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.67
Open5.71
Bid5.54 x 900
Ask6.66 x 3100
Day's Range5.60 - 5.74
52 Week Range4.24 - 7.40
Volume65,186
Avg. Volume281,998
Market Cap271.173M
Beta (5Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • Business Wire

    Kezar Life Sciences Announces Formation of Clinical Advisory Committee

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee.

  • Business Wire

    Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented by Richard Furie, M.D., Chief of Division of Rhe

  • Business Wire

    Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors

    Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors.